StemCyte International (TPE:4178) Net Margin %: -41.43% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:4178 StemCyte International Ltd TPE:4178
7 GF Score
Price NT$18.40
! 4 Warning Signs
View Full Analysis

What is StemCyte International Net Margin %?

StemCyte International TPE:4178 -2.39% 7 Net Margin % is -41.43% as of Mar. 2026. GuruFocus rates TPE:4178 with a GF Score™ of 7/100. The stock has 4 warning signs investors should review. Among 945 Biotechnology companies, StemCyte International ranks better than 55.45% on this metric.

Net margin is calculated as Net Income divided by its Revenue. StemCyte International's Net Income for the three months ended in Mar. 2026 was NT$-36.4 Mil. StemCyte International's Revenue for the three months ended in Mar. 2026 was NT$87.8 Mil. Therefore, StemCyte International's net margin for the quarter that ended in Mar. 2026 was -41.43%.

The historical rank and industry rank for StemCyte International's Net Margin % or its related term are showing as below:

TPE:4178' s Net Margin % Range Over the Past 10 Years
Min: -88.14   Med: -50.84   Max: -15.68
Current: -50.16

TPE:4178's Net Margin % is ranked better than
55.45% of 945 companies
in the Biotechnology industry
Industry Median: -85.59 vs TPE:4178: -50.16

StemCyte International  (TPE:4178) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

StemCyte International Net Margin % Related Terms

StemCyte International Net Margin % Historical Data

* Premium members only.

The historical data trend for StemCyte International's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

StemCyte International Net Margin % Chart

StemCyte International Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Net Margin %
-15.68 -88.14 -53.74 -47.93

StemCyte International Quarterly Data
Dec22 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only -34.09 -52.90 -50.39 -55.66 -41.43

TPE:4178 vs VRTX, REGN, RVMD: Net Margin % Comparison

For the Biotechnology subindustry, StemCyte International's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

StemCyte International Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, StemCyte International's Net Margin % distribution charts can be found below:

* The bar in red indicates where StemCyte International's Net Margin % falls into.


TPE:4178
7GF Score
StemCyte International Ltd TPE:4178
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

StemCyte International Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

StemCyte International's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-176.813/368.914
=-47.93 %

StemCyte International's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-36.383/87.809
=-41.43 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -41.43% mean?
StemCyte International (TPE:4178) has a Net Margin % of -41.43% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on StemCyte International and its competitors. According to the industry distribution chart, StemCyte International ranks #421 out of 945 companies in the Biotechnology industry, placing it in the top 44.6%.
Is StemCyte International's Net Margin % too high?
StemCyte International's current Net Margin % is -41.43%. Based on the distribution chart, StemCyte International ranks #421 out of 945 companies in the Biotechnology industry, which is above the industry midpoint. Overall, StemCyte International has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does StemCyte International's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, StemCyte International ranks #421 out of 945 companies for Net Margin %. This puts StemCyte International in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on StemCyte International and its competitors. StemCyte International's current Net Margin % is -41.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCyte International stock overvalued right now?
StemCyte International (TPE:4178) has a current Net Margin % of -41.43%. The current Net Margin % is -41.43%. StemCyte International's overall GF Score™ is 7/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For StemCyte International (TPE:4178), the current Net Margin % is -41.43% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

StemCyte International Business Description

Address Zhongxiao East Raod, 9th Floor-2, No. 508, Section 7, Nangang District, Taipei, TWN
StemCyte International Ltd is engaged in developing new stem cell drugs and test, process, and store umbilical cord blood (UCB)-related cells. The company's main operating activities are providing umbilical cord blood collection, processing and storage services. Its reportable segments are the United States, Taiwan, and Others. The majority of revenue is derived from the United States.
7GF Score

Get the complete analysis for TPE:4178

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$18.40
Price